Dental Adverse Effects of Anti-CD20 Therapies.

INTRODUCTION: Over the past few years, anti-CD20 therapies like rituximab, ocrelizumab or ofatumumab have seen an increase in interest in the treatment of neurological autoimmune disorders such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), or resistant forms of generalized myasthenia gravis (MG). They are generally well-tolerated, but recent reports have highlighted severe dental disorders in patients undergoing anti-CD20 therapies. The aim was to describe a series of cases and to compare with the available scientific literature. METHODS: We reviewed 6 patient cases with dental disorders during anti-CD20 therapy that were reported to the pharmacovigilance center. A disproportionality analysis was also conducted on Vigibase® for each anti-CD20 and each adverse effect described in the cases. RESULTS: Six cases of dental and gingival conditions in relatively young patients were reported (median age: 40.5 years old [min: 34; max: 79]). Oral conditions were developed in four patients with MS treated with ocrelizumab and in two patients receiving rituximab (one patient with MG and one with NMOSD). The onset of oral conditions ranged from 10 days to 2 years after treatment initiation. Notably, all patients treated with ocrelizumab experienced gingival recession. Various dental pathologies were observed, including tooth loss, dental pain, caries, brittle teeth, dental fractures, dental abscesses, and periodontitis. Analysis of Vigibase® revealed 284 worldwide cases of dental and gingival conditions under ocrelizumab, 386 cases under rituximab, and 80 under ofatumumab. Significant associations were found between these therapies and dental pathologies, particularly tooth abscesses and infections. CONCLUSION: To our knowledge, this is the first case series reporting dental conditions developed in patients long-term treated with anti-CD20 treatments. This issue, literature data, and Vigilyze® analysis might be considered a safety signal that necessitates being confirmed with more robust data, such as a retrospective study with a control group. Meanwhile, proactive measures are essential like frequent dental checkups and dental hygienic measures to prevent oral health problems associated with anti-CD20 therapies.

The impact of prenatal maternal mental health during the COVID-19 pandemic on birth outcomes: two nested case-control studies within the CONCEPTION cohort.

OBJECTIVE: Assess the association between prenatal mental health during the COVID-19 pandemic and preterm birth (PTB; delivery < 37 weeks gestation) and low birth weight (LBW; < 2500 g). METHODS: Pregnant individuals, > 18 years, were recruited in Canada and provided data through a web-based questionnaire. We analyzed data on persons recruited between 06/2020 and 08/2021 who completed questionnaires while pregnant and 2 months post-partum. Data on maternal sociodemographics, comorbidities, medication use, mental health (Edinburgh Postnatal Depression Scale, General Anxiety Disorder-7, stress), pandemic hardship (CONCEPTION-Assessment of Stress from COVID-19), and on gestational age at delivery and birth weight were self-reported. Crude and adjusted odds ratios (aOR) with 95% confidence interval (95%CI) were calculated to quantify the association between PTB/LBW and maternal mental health. RESULTS: A total of 1265 and 1233 participants were included in the analyses of PTB and LBW, respectively. No associations were observed between PTB and prenatal mental health (depression [aOR 1.01, 95%CI 0.91-1.11], anxiety [aOR 1.04, 95%CI 0.93-1.17], stress [aOR 0.88, 95%CI 0.71-1.10], or hardship [aOR 1.00, 95%CI 0.96-1.04]) after adjusting for potential confounders. The risk of PTB was increased with non-white ethnicity/race (aOR 3.85, 95%CI 1.35-11.00), consistent with the literature. Similar findings were observed for LBW (depression [aOR 1.03, 95%CI 0.96-1.13], anxiety [aOR 1.05, 95%CI 0.95-1.17], COVID stress [aOR 0.92, 95%CI 0.77-1.09], or overall hardship [aOR 0.97, 95%CI 0.94-1.01]). CONCLUSION: No association was found between prenatal mental health nor hardship during the COVID-19 pandemic and the risk of PTB or LBW. However, it is imperative to continue the follow-up of mothers and their offspring to detect long-term health problems early.

RéSUMé: OBJECTIF: Évaluer l'association entre la santé mentale prénatale pendant la pandémie de COVID-19 et les naissances prématurées (accouchement < 37 semaines de gestation) et les faibles poids à la naissance (< 2 500 g). MéTHODES: Des personnes enceintes de plus de 18 ans ont été recrutées au Canada et ont fourni des données prénatales via un questionnaire en ligne. Nous avons analysé les données des personnes recrutées entre 06/2020 et 08/2021, ayant rempli deux questionnaires dont un pendant la grossesse et un 2 mois post-partum. Les données sur les caractéristiques sociodémographiques maternelles, les comorbidités, l'utilisation de médicaments, la santé mentale (Échelle de dépression postnatale d'Édimbourg [EPDS], trouble anxieux généralisé-7 [GAD-7], stress), les difficultés liées à la pandémie (CONCEPTION­Évaluation du stress lié à la COVID-19) ainsi que l'âge gestationnel à l'accouchement et le poids à la naissance ont été auto-déclarées. Les rapports de cotes bruts et ajustés (aRC) avec un intervalle de confiance à 95% (IC 95%) ont été calculés pour quantifier l'association entre la prématurité/petit poids à la naissance et la santé mentale maternelle. RéSULTATS: Un total de 1 265 et 1 233 participants ont été inclus dans les analyses de NP et de FPN, respectivement. Aucune association n'a été observée entre la prématurité et la santé mentale prénatale (dépression [aRC 1,01, IC 95% 0,91­1,11], anxiété [aOR 1,04, IC 95% 0,93­1,17], stress [aRC 0,88, IC 95% 0,71­1,10], ni difficultés liées à la COVID-19 [aOR 1,00, IC 95% 0,96­1,04]) après ajustement pour les facteurs de confusion potentiels. Le risque de prématurité était plus élevé chez les personnes d'ethnie/race non blanche (aRC 3,85, IC 95% 1,35­11,00), en accord avec la littérature. Des résultats similaires ont été observés pour le faible poids à la naissance (dépression [aRC 1,03, IC 95% 0,96­1,13], anxiété [aRC 1,05, IC 95% 0,95­1,17], stress lié à la COVID [aRC 0,92, IC 95% 0,77­1,09], ou difficultés en lien avec la COVID-19 [aRC 0,97, IC 95% 0,94­1,01]). CONCLUSION: Aucune association n'a été trouvée entre la santé mentale prénatale ni les difficultés pendant la pandémie de COVID-19 et le risque de prématurité ou de petit poids à la naissance. Cependant, il est impératif de poursuivre le suivi des mères et de leurs enfants pour détecter précocement d'éventuels problèmes de santé à long terme.